KR20160098257A - 세포독성 펩티드 및 그의 접합체 - Google Patents

세포독성 펩티드 및 그의 접합체 Download PDF

Info

Publication number
KR20160098257A
KR20160098257A KR1020167015935A KR20167015935A KR20160098257A KR 20160098257 A KR20160098257 A KR 20160098257A KR 1020167015935 A KR1020167015935 A KR 1020167015935A KR 20167015935 A KR20167015935 A KR 20167015935A KR 20160098257 A KR20160098257 A KR 20160098257A
Authority
KR
South Korea
Prior art keywords
alkyl
independently selected
nhc
mmol
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167015935A
Other languages
English (en)
Korean (ko)
Inventor
베른하르드 가이어스탄거
얀 그뤼네발트
웨이지아 오우
테츠오 우노
용친 완
싱 왕
윤호 진
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160098257A publication Critical patent/KR20160098257A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A61K47/48438—
    • A61K47/48569—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167015935A 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체 Ceased KR20160098257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917293P 2013-12-17 2013-12-17
US61/917,293 2013-12-17
PCT/US2014/070800 WO2015095301A2 (en) 2013-12-17 2014-12-17 Cytotoxic peptides and conjugates thereof

Publications (1)

Publication Number Publication Date
KR20160098257A true KR20160098257A (ko) 2016-08-18

Family

ID=52463118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015935A Ceased KR20160098257A (ko) 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체

Country Status (16)

Country Link
US (3) US9988420B2 (cg-RX-API-DMAC7.html)
EP (2) EP3082877B1 (cg-RX-API-DMAC7.html)
JP (2) JP6636925B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160098257A (cg-RX-API-DMAC7.html)
CN (1) CN105899526A (cg-RX-API-DMAC7.html)
AU (1) AU2014364812B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016012538A2 (cg-RX-API-DMAC7.html)
CA (1) CA2930614A1 (cg-RX-API-DMAC7.html)
EA (1) EA201691251A1 (cg-RX-API-DMAC7.html)
ES (1) ES2758506T3 (cg-RX-API-DMAC7.html)
IL (1) IL245558B (cg-RX-API-DMAC7.html)
MX (1) MX2016007865A (cg-RX-API-DMAC7.html)
PL (1) PL3082877T3 (cg-RX-API-DMAC7.html)
PT (1) PT3082877T (cg-RX-API-DMAC7.html)
SG (1) SG11201604877UA (cg-RX-API-DMAC7.html)
WO (1) WO2015095301A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014214751B2 (en) * 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
WO2015095952A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Var2csa-drug conjugates
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
WO2015138615A2 (en) * 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
TW202014209A (zh) * 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
CN113365969B (zh) * 2018-11-23 2023-09-15 上海药明合联生物技术有限公司 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途
US20230129674A1 (en) * 2020-03-09 2023-04-27 Sigma-Aldrich Co. Llc Efficient preparation of dolastatin and auristatin analogs through a common intermediate
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP7670072B2 (ja) * 2021-01-18 2025-04-30 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
CN119894535A (zh) * 2022-07-27 2025-04-25 祐方有限公司 奥瑞他汀衍生物及其偶联物
WO2024152000A1 (en) * 2023-01-13 2024-07-18 The Trustees Of The University Of Pennsylvania Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof
AU2024256916A1 (en) 2023-04-18 2025-12-04 Astrazeneca Ab Conjugates comprising cleavable linkers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
ES2144421T3 (es) 1991-08-09 2000-06-16 Teikoku Hormone Mfg Co Ltd Nuevo derivado tetrapeptidico.
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
CN101287498B (zh) 2005-06-20 2013-03-27 Psma开发有限公司 Psma抗体-药物缀合物
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
ES2523033T3 (es) 2008-03-18 2014-11-20 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
EP2621508B1 (de) 2010-09-29 2015-08-26 Seattle Genetics, Inc. N-carboxyalkyl-auristatine und ihre verwendung
TWI545134B (zh) 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
WO2012113847A1 (en) 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
DK2714684T3 (en) 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
CA3111357A1 (en) * 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
BR112014030098A2 (pt) 2012-06-04 2017-07-25 Irm Llc métodos de rotulagem específica de sítio e moléculas produzidas pelos mesmos
AU2014214751B2 (en) * 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates

Also Published As

Publication number Publication date
JP6636925B2 (ja) 2020-01-29
WO2015095301A3 (en) 2015-09-03
AU2014364812A1 (en) 2016-07-07
CN105899526A (zh) 2016-08-24
US20180244717A1 (en) 2018-08-30
US20190382441A1 (en) 2019-12-19
MX2016007865A (es) 2017-01-11
AU2014364812B2 (en) 2017-05-25
US10787480B2 (en) 2020-09-29
CA2930614A1 (en) 2015-06-25
BR112016012538A2 (pt) 2017-09-26
JP2017503777A (ja) 2017-02-02
ES2758506T3 (es) 2020-05-05
US20160311853A1 (en) 2016-10-27
SG11201604877UA (en) 2016-07-28
PT3082877T (pt) 2019-12-03
EA201691251A1 (ru) 2016-11-30
PL3082877T3 (pl) 2020-02-28
EP3082877A2 (en) 2016-10-26
EP3082877B1 (en) 2019-08-28
US10392421B2 (en) 2019-08-27
IL245558B (en) 2020-01-30
EP3753578A1 (en) 2020-12-23
WO2015095301A2 (en) 2015-06-25
JP2020023514A (ja) 2020-02-13
IL245558A0 (en) 2016-06-30
US9988420B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
JP6636925B2 (ja) 細胞障害性ペプチドおよびその抱合体
EP3154997B1 (en) Auristatin derivatives and conjugates thereof
JP6498773B2 (ja) ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
JP2018502131A (ja) ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
JP2022533215A (ja) 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
TW201836645A (zh) 具有酵素可裂解基團的細胞毒性藥劑之前藥
EP3215519A1 (en) Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP2018528161A (ja) Ｋｓｐ阻害剤との部位特異的均一複合体
WO2017191579A1 (en) Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
KR20240067085A (ko) 항체 약물 접합체에 사용하기 위한 링커
KR102858995B1 (ko) 설포말레이미드계 링커 및 상응하는 컨쥬게이트
JP7023933B2 (ja) セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
KR20250133764A (ko) 링커, 약물 링커 및 그의 접합체 및 그의 사용 방법
TW202506691A (zh) Ｓｔｉｎｇ促效劑化合物及其結合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210324

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210324

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I